Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Reply to L. Casadaban et al.

Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.

J Clin Oncol. 2017 Apr 20;35(12):1373-1374. doi: 10.1200/JCO.2016.71.2646. Epub 2017 Jan 23. No abstract available.

PMID:
28113023
2.

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).

Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.

J Clin Oncol. 2016 Sep 1;34(25):3047-53. doi: 10.1200/JCO.2015.65.4699. Epub 2016 Jul 18.

3.

Analytical performance of a formalin-fixed paraffin-embedded tissue-based 634-probe prognostic assay for predicting outcome of patients with stage II colon cancer.

Plamadeala V, Huang S, McCreary SM, Reitze NJ, Ewing AL, Gabrin MJ, Bennett AE, Mulligan JM, Wilson CL, Wang D.

Appl Immunohistochem Mol Morphol. 2014 Apr;22(4):308-16. doi: 10.1097/PDM.0000000000000031.

PMID:
24717231
4.

Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer.

Mulligan JM, Hill LA, Deharo S, Irwin G, Boyle D, Keating KE, Raji OY, McDyer FA, O'Brien E, Bylesjo M, Quinn JE, Lindor NM, Mullan PB, James CR, Walker SM, Kerr P, James J, Davison TS, Proutski V, Salto-Tellez M, Johnston PG, Couch FJ, Paul Harkin D, Kennedy RD.

J Natl Cancer Inst. 2014 Jan;106(1):djt335. doi: 10.1093/jnci/djt335.

5.

Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue.

Kennedy RD, Bylesjo M, Kerr P, Davison T, Black JM, Kay EW, Holt RJ, Proutski V, Ahdesmaki M, Farztdinov V, Goffard N, Hey P, McDyer F, Mulligan K, Mussen J, O'Brien E, Oliver G, Walker SM, Mulligan JM, Wilson C, Winter A, O'Donoghue D, Mulcahy H, O'Sullivan J, Sheahan K, Hyland J, Dhir R, Bathe OF, Winqvist O, Manne U, Shanmugam C, Ramaswamy S, Leon EJ, Smith WI Jr, McDermott U, Wilson RH, Longley D, Marshall J, Cummins R, Sargent DJ, Johnston PG, Harkin DP.

J Clin Oncol. 2011 Dec 10;29(35):4620-6. doi: 10.1200/JCO.2011.35.4498. Epub 2011 Nov 7.

PMID:
22067406
6.

Profiling of the BRCA1 transcriptome through microarray and ChIP-chip analysis.

Gorski JJ, Savage KI, Mulligan JM, McDade SS, Blayney JK, Ge Z, Harkin DP.

Nucleic Acids Res. 2011 Dec;39(22):9536-48. doi: 10.1093/nar/gkr679. Epub 2011 Aug 31.

7.

Generation of a non-small cell lung cancer transcriptome microarray.

Tanney A, Oliver GR, Farztdinov V, Kennedy RD, Mulligan JM, Fulton CE, Farragher SM, Field JK, Johnston PG, Harkin DP, Proutski V, Mulligan KA.

BMC Med Genomics. 2008 May 30;1:20. doi: 10.1186/1755-8794-1-20.

8.

BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy.

Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, Mullan PB, Johnston PG, Wilson RH, Harkin DP.

Clin Cancer Res. 2007 Dec 15;13(24):7413-20.

9.

Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.

Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, James CR, Farragher SM, Mulligan JM, Scott AN, Dervan PA, Johnston PG, Couch FJ, Daly PA, Kay E, McCann A, Mullan PB, Harkin DP.

J Natl Cancer Inst. 2007 Nov 21;99(22):1683-94. Epub 2007 Nov 13.

10.

Spinal cord injury without radiographic abnormality in a 4-year-old child: hypoperfusion injury or direct trauma?

Mulligan JM, Miller T, McGuffie AC, Graham CA.

Eur J Emerg Med. 2007 Aug;14(4):216-8.

PMID:
17620913
11.

BRCA1 regulates IFN-gamma signaling through a mechanism involving the type I IFNs.

Buckley NE, Hosey AM, Gorski JJ, Purcell JW, Mulligan JM, Harkin DP, Mullan PB.

Mol Cancer Res. 2007 Mar;5(3):261-70.

12.

Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines.

Mulligan JM, Greene LM, Cloonan S, Mc Gee MM, Onnis V, Campiani G, Fattorusso C, Lawler M, Williams DC, Zisterer DM.

Mol Pharmacol. 2006 Jul;70(1):60-70. Epub 2006 Mar 29.

PMID:
16571652
13.

Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human astrocytoma cells by the pyrrolo-1,5-benzoxazepine, PBOX-21.

Mulligan JM, Campiani G, Ramunno A, Nacci V, Zisterer DM.

Biochim Biophys Acta. 2003 Sep 1;1639(1):43-52.

14.
15.

A 15-year experience with varicella infections in a pediatric burn unit.

Sheridan RL, Weber JM, Pasternak MM, Mulligan JM, Tompkins RG.

Burns. 1999 Jun;25(4):353-6.

PMID:
10431985
16.

Supplemental Content

Loading ...
Support Center